Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
GAITHERSBURG, Md. , Jan. 09, 2024 (GLOBE NEWSWIRE) — Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving,...
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
GAITHERSBURG, Md. , Nov. 28, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the...
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
GAITHERSBURG, Md. , Nov. 24, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today confirmed that on November 16, 2023 , the New York Stock Exchange (NYSE) sent a notice that the...
Emergent BioSolutions Reports Third Quarter 2023 Financial Results
Third Quarter 2023 Total Revenues of $271M , above the prior guidance range Third Quarter 2023 Pre-Tax Loss of $(266)M and Adjusted EBITDA (2) of $20M Updates FY 2023 guidance GAITHERSBURG, Md. ,...
UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
GAITHERSBURG, Md. , Oct. 30, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) has rescheduled its conference call to Wednesday, November 8 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
GAITHERSBURG, Md. , Oct. 19, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 2, 2023 , at 5:00 pm eastern time to discuss the...
Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
Professional Football Hall of Famer partners with Emergent to raise awareness of the dangers of opioid use and the importance of being prepared with NARCAN ® Nasal Spray The life-saving medicine is...
Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
GAITHERSBURG, Md. , Oct. 02, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective...
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
Emergent has officially shipped its over the counter, original prescription strength NARCAN ® Naloxone HCl Nasal Spray 4 mg to leading mass, drug/pharmacy and grocery stores, as well as online...
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
Reports Q2 2023 total revenues of $338M , above the prior guidance range, net loss of $261M and adjusted EBITDA of $56M Updates FY 2023 guidance and provides initial Q3 2023 forecast for total...
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
Actions bring sharpened focus on MCM and NARCAN ® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost savings over $100 million annually GAITHERSBURG, Md. ,...
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
GAITHERSBURG, Md. , July 31, 2023 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and...